Samsung's $3.5 billion investment in French AI startup Mistral signals global demand for AI infrastructure even as biotech stocks like Ionis and Novartis face setbacks after disappointing drug trial results
Samsung's leadership of a $3.5 billion funding round for Mistral, a private French artificial intelligence lab, signaled to U.S. investors that demand for AI infrastructure is not only robust but expanding well beyond Silicon Valley. This deal, which doubled Mistral's valuation to $24 billion within a year, attracted major players such as Nvidia and ASML, making it the largest technology funding round in European history. As reported in a Reuters financial review, the Series D round also stands as the largest equity financing ever for a private European technology company, highlighting the scale of investor confidence in the sector.
Mistral, founded just three years ago, has rapidly approached the scale of leading U.S. AI labs, with its latest funding round following a previous surge in valuation.
AI Funding Moves Beyond Silicon Valley
Mistral's recent funding round is significant not only for its size but also for its broader implications. The involvement of Samsung, Nvidia, and ASML indicates that global chipmakers and technology leaders anticipate sustained demand for AI computing power. The round was co-led by PSG Equity, Samsung, and the EU-backed Scaleup Europe Fund, marking the first participation of this European sovereign fund in such a transaction, as detailed in Reuters reporting. As more AI labs like Mistral emerge outside the U.S., the market for advanced chips, data centers, and supporting infrastructure is becoming increasingly geographically diverse. For companies such as Nvidia, each new AI lab represents an additional channel for high-margin hardware sales.
The Mistral Series D round was jointly led by PSG Equity, Samsung Electronics, and the Scaleup Europe Fund, with the latter participating for the first time in such a major tech deal.
Biotech Faces Setbacks After Drug Trial Misses
In contrast to AI's upward trajectory, the biotech sector is contending with scientific and financial challenges. On September 5, 2026, Novartis announced that its large-scale trial of pelacarsen, a drug licensed from Ionis Pharmaceuticals, did not demonstrate a statistically significant reduction in major cardiovascular events. Although the drug safely lowered lipoprotein(a) levels, this did not result in fewer heart attacks or strokes compared to placebo. The outcome led to sharp pre-market declines for both companies and raised questions about the prospects of similar drugs in development at Amgen and Eli Lilly, as reported by Reuters.
The financial implications for Ionis are considerable. The company could earn royalties in the mid-teens to low-20% range, along with up to $650 million in milestone payments if pelacarsen succeeds. This marks Ionis's second major cardiovascular disappointment this year, following a failed trial with AstraZeneca in July. Investors are now awaiting more detailed data from Novartis to assess whether higher doses might still provide clinical benefit, or if the entire drug class faces a fundamental challenge.
Growth Versus Profit in Software and Retail
Beyond AI and biotech, several U.S. software and retail companies are under investor scrutiny as they release earnings and update guidance. Braze, a customer engagement software provider, reported $211 million in quarterly revenue, surpassing Wall Street expectations for the fourth consecutive quarter, though earnings fell short of targets. ServiceTitan, which develops software for home services businesses, is positioning its AI product as a new profit driver and forecasts $1.14 billion in revenue for fiscal 2027. Casey's General Stores, a convenience store chain, is emphasizing same-store sales growth and the integration of newly acquired locations to sustain momentum.
Other companies, including Oracle, Adobe, and Chewy, are facing their own challenges. Oracle's cloud infrastructure spending and enterprise demand will be closely monitored after a sharp stock decline last quarter. Adobe is under pressure to demonstrate that its AI-driven revenue growth is sustainable amid intensifying competition. Chewy is navigating a more challenging consumer environment and is relying on recent acquisitions to support earnings, but faces risks associated with rapid expansion through deals rather than organic growth.
Reinvention and Risk in Data Security
Rubrik, a data security company, distinguishes itself through rapid reinvention in a sector where product cycles are shortening. Its software enables organizations to recover from cyberattacks within hours by restoring clean backup files, a capability that has driven net retention rates above 120%. Rubrik reported 38% revenue growth in its most recent quarter and achieved profitability after a year of losses, with both value and growth-focused investment teams projecting the potential for shares to more than double over five years if current trends persist.
For investors evaluating opportunities across AI, biotech, software, and security, the current environment is marked by sharp contrasts. AI infrastructure is attracting global capital at record levels, while biotech faces renewed skepticism following high-profile trial failures. Software and retail companies are being assessed on their ability to convert growth into sustainable profits, and data security firms are rewarded for rapid adaptation. The key takeaway for U.S. investors: capital is flowing to sectors where demand is tangible and growth is supported by operational results, not just expectations.
AI infrastructure spending has become a global phenomenon, with chipmakers and technology firms investing heavily in new labs and data centers outside the U.S. According to the Semiconductor Industry Association, global semiconductor sales reached $574 billion in 2024, with AI-related demand driving much of the recent growth. Meanwhile, the biotech sector remains highly sensitive to clinical trial outcomes, as a single failed study can erase billions in market value and reshape the outlook for entire drug classes. For investors, understanding the mechanisms behind these shifts-whether the capital intensity of AI or the binary risks of drug development-is essential for navigating today's markets.
